VVOS Earnings Vivos Therapeutics, Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–17 of 17
| Q1 2026 | 2026-03-31 | -0.52 | 2026-05-20 | 10-Q |
| FY 2025 | 2025-12-31 | -2.07 | 2026-04-15 | 10-K |
| Q3 2025 | 2025-09-30 | -1.49 | 2025-11-19 | 10-Q |
| Q2 2025 | 2025-06-30 | -1.00 | 2025-08-19 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.45 | 2026-05-20 | 10-Q |
| FY 2025 | 2024-12-31 | -2.22 | 2026-04-15 | 10-K |
| Q3 2025 | 2024-09-30 | -1.94 | 2025-11-19 | 10-Q |
| Q2 2025 | 2024-06-30 | -2.06 | 2025-08-19 | 10-Q |
| Q1 2025 | 2024-03-31 | -1.63 | 2025-05-15 | 10-Q |
| FY 2024 | 2023-12-31 | -11.14 | 2025-03-31 | 10-K |
| Q3 2024 | 2023-09-30 | -8.09 | 2024-11-14 | 10-Q |
| Q2 2024 | 2023-06-30 | -6.40 | 2024-08-14 | 10-Q |
| Q1 2024 | 2023-03-31 | -1.72 | 2024-05-14 | 10-Q |
| FY 2023 | 2022-12-31 | -25.90 | 2024-03-28 | 10-K |
| Q3 2023 | 2022-09-30 | -20.90 | 2023-11-14 | 10-Q |
| Q2 2023 | 2022-06-30 | -0.58 | 2023-08-16 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.25 | 2023-06-08 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.